Alocrest™ (Vinorelbine Optisome™)

A combination of modern nanoparticle technology and a potent lung and breast cancer chemotherapy

Vinorelbine (VRL) is widely used as a single-agent and as part of combination therapy in the treatment of advanced non-small cell lung cancer and breast cancer. VRL therapy is limited by its cell cycle-specific (M-phase) activity combined with a short plasma half-life and frequent dose reductions in anticipation of significant myelo-suppression in the primarily elderly target population. Alocrest™ is VRL encapsulated in sphingomyelin and cholesterol nanoparticles called Optisomes™. Optisomal encapsulation has the potential to facilitate convenient, full-dose VRL delivery in a manner that can overcome the limitations of conventional VRL and improve efficacy.

Preclinical data demonstrate the value of Alocrest over VRL

- **Prolonged circulation and 100-fold increased plasma AUC**
- **9.5-fold increased VRL exposure (tissue AUC) at tumor sites**
- **Up to a 3.5-fold increased therapeutic index in xenograft models compared to unencapsulated VRL**



Completed Phase I dose-escalation trial demonstrated promising anti-cancer activity as well as acceptable and predictable toxicity

- **46% disease control rate across a broad range of doses**
- **Maximum tolerated dose in heavily pretreated patients that is comparable to that of unencapsulated VRL**
- **Reversible neutropenia was the most common DLT**
- **No peripheral venous irritation**

Planned clinical trials will support EMEA and FDA approval

Significant commercial value based on the potential for wide-spread

HANA BIOSCIENCES

Gradon Knotts
Vice President-Business Development
7000 Shoreline Court, Suite 370
South San Francisco, California 94080

Main Phone: 650-588-6404
Direct Phone: 650-228-5048
Cell Phone: 650-823-0509
Fax: 650-228-5049

Email: gradon.knotts@hanabiosciences.com